Brantford needs a HART Hub to address addictions, mental health, Mayor - Brantford Expositor

Hart stopped 24 of 27 shots in Monday's 4-2 loss to the Wild. Minnesota's fourth goal was an empty-netter late in the third period. Hart endured a difficult opening period, allowing goals to Matt Boldy, Maxim Shabanov and Danila Yurov within a 5:07 span. The veteran netminder settled down afterward, keeping Minnesota off the scoreboard for the rest of his appearance, but the damage was already done, and the Wild clinched the victory with an empty-netter from Joel Eriksson Ek. This was Hart's second loss of the season, and the second time in five starts he's allowed more than two goals. The netminder is likely to be on the bench against the Predators on Tuesday in the second leg of a back-to-back set, but he could return to the starting lineup against the Flames on Thursday.

Continuous glucose monitors (CGMs) could transform diabetes management for millions of Americans with type 2 diabetes who don't take insulin, according to findings published in the New England Journal of Medicine. The clinical trial found that adults using CGMs spent approximately five additional hours each day within their target blood sugar range compared with those receiving routine care. Nearly twice as many CGM users also achieved an A1c level below 7%, a common treatment goal for people with diabetes.

Patients who wore noise-canceling headphones during minimally invasive gynecological surgery were significantly less likely to experience postoperative nausea and vomiting (PONV), suggest findings from a randomized clinical trial presented at the Anesthesiology 2026 annual meeting.

“Beyond Detecting Cancer Recurrence: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? An exciting new study published in The Oncologist highlights the clinical potential of Signatera Genome, a whole-genome sequencing (WGS)-based, tumor-informed circulating tumor DNA (ctDNA) assay, not only for detecting molecular residual disease (MRD), but also for potentially informing adjuvant treatment decisions.